Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.
This will hopefully liven up the company's pipeline, which has been sluggish of late.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
Senior Manager, QA GMP 
Scientist Radiochemistry 
Senior Drug Product Specialist 
Pharmacovigilance & Regulatory Officer 
Senior CMC Regulatory Manager 
Chief Business Officer 
Sales Manager Denmark 
Ambitious Business Relationship Manager for the Danish Medicines Agency 
Manager of QA, BHS Logistics 
Drug Safety Associate 
Lab Manager 
Senior/lead consultant at Emendo Engineering 
Product specialist in Cardio Rhythm Management, Zealand 
Vice President, Medical Affairs 
Clinical Project Lead 
Product specialist